Hoppe, JE;
Kasi, AS;
Pittman, JE;
Jensen, R;
Thia, LP;
Robinson, P;
Tirakitsoontorn, P;
... Davies, G; + view all
(2025)
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.
The Lancet Respiratory Medicine
10.1016/S2213-2600(24)00407-7.
(In press).